Organigram (OGI) Competitors

C$1.60 +0.04 (+2.56%)

As of 05/25/2026 03:59 PM Eastern

OGI vs. CMED, WEED, EMC, ICC, and LEAF

Should you buy Organigram stock or one of its competitors? MarketBeat compares Organigram with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organigram include CanniMed Therapeutics (CMED), Canopy Growth (WEED), Emblem (EMC), ICC Labs (ICC), and Leaf Mobile (LEAF). These companies are all part of the "cannabis" industry.

How does Organigram compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Organigram (TSE:OGI) are both small-cap cannabis companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organigram has a consensus target price of C$3.13, suggesting a potential upside of 95.31%. Given Organigram's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

CanniMed Therapeutics has higher earnings, but lower revenue than Organigram.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A
Organigram	C$274.19M	0.82	-C$57.23M	-C$0.21	N/A

In the previous week, Organigram had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Organigram and 0 mentions for CanniMed Therapeutics. Organigram's average media sentiment score of 1.00 beat CanniMed Therapeutics' score of 0.00 indicating that Organigram is being referred to more favorably in the news media.

Company	Overall Sentiment
CanniMed Therapeutics	Neutral
Organigram	Positive

CanniMed Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -9.19%. CanniMed Therapeutics' return on equity of 0.00% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CanniMed Therapeutics	N/A	N/A	N/A
Organigram	-9.19%	-6.83%	-5.56%

Summary

Organigram beats CanniMed Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Organigram compare to Canopy Growth?

Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Organigram has a net margin of -9.19% compared to Canopy Growth's net margin of -117.31%. Organigram's return on equity of -6.83% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-117.31%	-52.88%	-3.83%
Organigram	-9.19%	-6.83%	-5.56%

Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$278.39M	2.29	-C$1.05B	-C$1.86	N/A
Organigram	C$274.19M	0.82	-C$57.23M	-C$0.21	N/A

Canopy Growth has a beta of 1.605535, meaning that its share price is 61% more volatile than the broader market. Comparatively, Organigram has a beta of 1.722534, meaning that its share price is 72% more volatile than the broader market.

Canopy Growth presently has a consensus target price of C$1.97, indicating a potential upside of 30.24%. Organigram has a consensus target price of C$3.13, indicating a potential upside of 95.31%. Given Organigram's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.6% of Canopy Growth shares are owned by institutional investors. Comparatively, 4.0% of Organigram shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Canopy Growth had 1 more articles in the media than Organigram. MarketBeat recorded 2 mentions for Canopy Growth and 1 mentions for Organigram. Organigram's average media sentiment score of 1.00 beat Canopy Growth's score of 0.27 indicating that Organigram is being referred to more favorably in the news media.

Company	Overall Sentiment
Canopy Growth	Neutral
Organigram	Positive

Summary

Organigram beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

How does Organigram compare to Emblem?

Organigram (TSE:OGI) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Organigram presently has a consensus price target of C$3.13, suggesting a potential upside of 95.31%. Given Organigram's stronger consensus rating and higher possible upside, equities analysts plainly believe Organigram is more favorable than Emblem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Emblem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Emblem has a net margin of 0.00% compared to Organigram's net margin of -9.19%. Emblem's return on equity of 0.00% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-9.19%	-6.83%	-5.56%
Emblem	N/A	N/A	N/A

Emblem has lower revenue, but higher earnings than Organigram. Emblem is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$274.19M	0.82	-C$57.23M	-C$0.21	N/A
Emblem	$5.71M	43.02	-$24.81M	-$0.19	N/A

In the previous week, Organigram had 1 more articles in the media than Emblem. MarketBeat recorded 1 mentions for Organigram and 0 mentions for Emblem. Organigram's average media sentiment score of 1.00 beat Emblem's score of 0.00 indicating that Organigram is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram	Positive
Emblem	Neutral

Summary

Organigram beats Emblem on 9 of the 15 factors compared between the two stocks.

How does Organigram compare to ICC Labs?

Organigram (TSE:OGI) and ICC Labs (CVE:ICC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

ICC Labs has a net margin of 0.00% compared to Organigram's net margin of -9.19%. ICC Labs' return on equity of 0.00% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-9.19%	-6.83%	-5.56%
ICC Labs	N/A	N/A	N/A

Organigram presently has a consensus target price of C$3.13, indicating a potential upside of 95.31%. Given Organigram's stronger consensus rating and higher probable upside, research analysts plainly believe Organigram is more favorable than ICC Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ICC Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Organigram had 1 more articles in the media than ICC Labs. MarketBeat recorded 1 mentions for Organigram and 0 mentions for ICC Labs. Organigram's average media sentiment score of 1.00 beat ICC Labs' score of 0.00 indicating that Organigram is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram	Positive
ICC Labs	Neutral

ICC Labs has lower revenue, but higher earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$274.19M	0.82	-C$57.23M	-C$0.21	N/A
ICC Labs	C$533.68K	419.04	C$2.35M	C$0.02	95.29

Summary

Organigram beats ICC Labs on 8 of the 15 factors compared between the two stocks.

How does Organigram compare to Leaf Mobile?

Organigram (TSE:OGI) and Leaf Mobile (TSE:LEAF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Organigram currently has a consensus price target of C$3.13, indicating a potential upside of 95.31%. Given Organigram's stronger consensus rating and higher possible upside, equities research analysts plainly believe Organigram is more favorable than Leaf Mobile.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Leaf Mobile	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Leaf Mobile has a net margin of 0.00% compared to Organigram's net margin of -9.19%. Leaf Mobile's return on equity of 0.00% beat Organigram's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	-9.19%	-6.83%	-5.56%
Leaf Mobile	N/A	N/A	N/A

Leaf Mobile has lower revenue, but higher earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Leaf Mobile, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$274.19M	0.82	-C$57.23M	-C$0.21	N/A
Leaf Mobile	C$83.74M	0.00	C$3.37M	C$0.04	N/A

4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Organigram had 1 more articles in the media than Leaf Mobile. MarketBeat recorded 1 mentions for Organigram and 0 mentions for Leaf Mobile. Organigram's average media sentiment score of 1.00 beat Leaf Mobile's score of 0.00 indicating that Organigram is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram	Positive
Leaf Mobile	Neutral

Summary

Organigram beats Leaf Mobile on 8 of the 14 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export

Metric	Organigram	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$225.24M	C$2.22B	C$6.46B	C$12.16B
Dividend Yield	N/A	2.95%	2.76%	6.20%
P/E Ratio	-7.48	5.16	21.22	37.64
Price / Sales	0.82	1,770.59	553.92	11.68
Price / Cash	3.85	10.18	43.49	82.29
Price / Book	0.57	10.61	10.37	4.50
Net Income	-C$57.23M	C$20.70B	C$3.57B	C$299.09M
7 Day Performance	10.34%	8.23%	6.40%	2.48%
1 Month Performance	-18.78%	3.77%	3.52%	1.47%
1 Year Performance	-14.89%	22.84%	34.02%	53.55%

Organigram Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	3.5356 of 5 stars	C$1.60 +2.6%	C$3.13 +95.3%	-14.4%	C$225.24M	C$274.19M	N/A	987	Positive News
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
WEED Canopy Growth	2.4568 of 5 stars	C$1.51 -2.6%	C$1.97 +30.2%	-39.8%	C$655.37M	C$278.39M	N/A	2,700
EMC Emblem	N/A	$1.88 +1.6%	N/A	+0.0%	$245.45M	$5.71M	N/A	N/A
ICC ICC Labs	N/A	C$1.62 -5.8%	N/A	+0.0%	C$223.64M	C$533.68K	95.29	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:OGI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organigram (OGI) Competitors

OGI vs. CMED, WEED, EMC, ICC, and LEAF

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Canopy Growth?

Summary

How does Organigram compare to Emblem?

Summary

How does Organigram compare to ICC Labs?

Summary

How does Organigram compare to Leaf Mobile?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organigram (OGI) Competitors

OGI vs. CMED, WEED, EMC, ICC, and LEAF

How does Organigram compare to CanniMed Therapeutics?

Do institutionals and insiders have more ownership in CMED or OGI?

Do analysts rate CMED or OGI?

Which has better earnings and valuation, CMED or OGI?

Does the media refer more to CMED or OGI?

Is CMED or OGI more profitable?

Summary

How does Organigram compare to Canopy Growth?

Is WEED or OGI more profitable?

Which has preferable valuation & earnings, WEED or OGI?

Which has more volatility and risk, WEED or OGI?

Do analysts rate WEED or OGI?

Do insiders & institutionals believe in WEED or OGI?

Does the media prefer WEED or OGI?

Summary

How does Organigram compare to Emblem?

Do analysts rate OGI or EMC?

Do insiders and institutionals hold more shares of OGI or EMC?

Is OGI or EMC more profitable?

Which has higher earnings and valuation, OGI or EMC?

Does the media favor OGI or EMC?

Summary

How does Organigram compare to ICC Labs?

Is OGI or ICC more profitable?

Do analysts recommend OGI or ICC?

Do institutionals & insiders believe in OGI or ICC?

Does the media refer more to OGI or ICC?

Which has better earnings & valuation, OGI or ICC?

Summary

How does Organigram compare to Leaf Mobile?

Do analysts rate OGI or LEAF?

Is OGI or LEAF more profitable?

Which has higher valuation and earnings, OGI or LEAF?

Do institutionals & insiders believe in OGI or LEAF?

Does the media refer more to OGI or LEAF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools